Nephrogen
PrivateLast Round
Pre Seed
Nov 28, 2025
Est. Valuation
$1.79M
Total Funding Raised
$2.65M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Nephrogen operates in Healthcare & Life Sciences and is based in New York City, New York. Its latest recorded funding round was a Pre Seed round in November 2025.
Nephrogen is a biotechnology company that develops curative gene and genomic therapies for kidney and pancreatic conditions using its proprietary AI-driven NeFIND™ platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Medical AI, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Infrastructure
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Nephrogen Comparables
Compare Nephrogen with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Nionyx Bio | 87% | |
| Lir Therapeutics | 82% | |
| Avista Therapeutics | 81% |
For institutional investors. Book with your work email.
Nephrogen Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Pre Seed | Nov 28, 2025 | ||||
| Seed | Oct 27, 2025 | ||||
| Grant | Nov 15, 2024 | ||||
| Grant | Jul 13, 2023 | ||||
| Accelerator | Aug 31, 2020 | ||||
Accelerator | Jun 1, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Nephrogen Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| StartX | Accelerator |
| Gaingels | Seed |
| Empire State Development | Grant |
| ZAKA VC | Pre Seed |
| 2048 Ventures | Grant |
| Y Combinator | Accelerator |
| National Institutes of Health (NIH) | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 28, 2025
$2M round led by ZAKA VC
- Oct 27, 2025
$4M round completed.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventSep 3, 2026
Nephrogenbiotech co-founder and CEO Demetri Maxim comes in second at TechCrunch Startup Battlefield 2025.
For institutional investors. Book with your work email.
Nephrogen Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Nephrogen's valuation, stock price, and market status.
Is Nephrogen a public or private company?
Nephrogen is a private company.
What is the current stock price of Nephrogen?
Nephrogen is a private company, so its shares have no public market price. Caplight tracks Nephrogen's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Nephrogen worth (valuation)?
Nephrogen's valuation is estimated at $1.8M based on funding round data.
Can I buy Nephrogen stock?
Nephrogen shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Nephrogen's last funding round?
Nephrogen's most recent funding round was Pre Seed on November 28, 2025.
Who are the main investors in Nephrogen?
Key investors in Nephrogen include Y Combinator.
Will Nephrogen IPO soon?
No public IPO plans have been announced for Nephrogen.
How can I track Nephrogen secondary market activity?
Caplight tracks bids, offers, and trades in Nephrogen's shares on secondary markets.